According to a new study, dupilumab-induced ocular surface disease (DIOSD) appears to occur more frequently in patients with atopic dermatitis (AD) than in patients with other conditions being treated with the biologic.
According to a new study, dupilumab-induced ocular surface disease (DIOSD) appears to occur more frequently in patients with atopic dermatitis (AD) than in patients with other conditions being treated with the biologic.